According to Huang et al.(Huang et al., 2022), a in situ DC-primed vaccine drastically facilitated CD8+ T cell responses, which resulted in obvious tumor suppression in TNBC mouse xenograft model and patient-derived tumor organoids. This evidence concerns the gene CD8A and neoplasm.